# Pharmacokinetics of Dabrafenib in Subjects With Hepatic Impairment

> **NCT02873650** · PHASE1 · TERMINATED · sponsor: **Novartis Pharmaceuticals** · enrollment: 5 (actual)

## Conditions studied

- Hepatic Impairment

## Interventions

- **DRUG:** dabrafenib

## Key facts

- **NCT ID:** NCT02873650
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2016-12-20
- **Primary completion:** 2018-10-12
- **Final completion:** 2019-04-08
- **Target enrollment:** 5 (ACTUAL)
- **Why stopped:** Study was terminated due to continued enrolment difficulties.
- **Last updated:** 2020-12-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02873650

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02873650, "Pharmacokinetics of Dabrafenib in Subjects With Hepatic Impairment". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT02873650. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*